Cylerion Therapeutics, Inc. (NASDAQ: CYCN), a biopharmaceutical company whose mission is to develop treatments that restore cognitive function, recently reported financial results for 2Q2021 and provided general corporate and pipeline updates. Second-quarter summary The company’s cash and cash equivalents at the end of the second quarter were approximately $70 million, […]